Data from the RATIONALE 305 trial support the approval of tislelizumab/chemotherapy in unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma.
Approval Alert | Tislelizumab/Chemotherapy in Gastric/GEJ Adenocarcinoma
Advertisement
Advertisement
Trending on CancerNetwork
1
One of “The Best Opportunities” for Long-Term Remission in Multiple Myeloma
2
Blood-Based Lung Cancer Screening Tool Earns FDA Breakthrough Device Status
3
What Does Priority Review Mean for Subcutaneous Amivantamab in HNSCC?
4
What Are The Biggest Misconceptions About CAR T Cells in Multiple Myeloma?
5